Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. (Q37629827)

21 August 2017

1 reference

title

Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. (English)

1 reference

21 August 2017

1 reference

2

Carlos Escobar

1 reference

21 August 2017

Vivencio Barrios

1

1 reference

21 August 2017

language of work or name

1 reference

1 November 2009

1 reference

Expert Review of Cardiovascular Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

7

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

1317-1327

1 reference

Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Forty-year mortality from cardiovascular diseases and all causes of death in the US Railroad cohort of the Seven Countries Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Structural mechanism for statin inhibition of HMG-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using R

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia--Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

A randomized trial of rosuvastatin in the prevention of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Lipid screening and cardiovascular health in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Statin treatment in children with familial hypercholesterolemia: the younger, the better

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Rationale and design of the carotid plaque in human for all evaluations with aggressive rosuvastatin therapy (CHALLENGER trial): evaluation by magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Thematic review series: patient-oriented research. Imaging atherosclerosis: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Meta-analysis of the studies assessing temporal changes in coronary plaque volume using intravascular ultrasound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Carotid plaque composition differs between ethno-racial groups: an MRI pilot study comparing mainland Chinese and American Caucasian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

The safety of statins in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Statin use in heart failure: a cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Lipid levels after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

21 January 2018

Safety of rosuvastatin

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Dose-dependent effect of rosuvastatin treatment on urinary protein excretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

Rosuvastatin-induced arrest in progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.119

21 January 2018

Identifiers

DOI

10.1586/ERC.09.119

1 reference

21 August 2017

1 reference